-

Sinovac Shareholders Vote to Remove Current Directors and Elect SAIF Partners Nominees to Board at Special Meeting

Shareholders Voted to Approve Both SAIF Partners Proposals at Special Meeting

Newly Elected Directors Are Committed to Support and Execute the Announced Payout of Dividends and Unlock Sinovac’s Long-Term Value for All Shareholders Through the Resumption of Trading of Sinovac’s Common Shares

NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), today announced that Sinovac Biotech Ltd. (“Sinovac” or the “Company”) shareholders voted to approve SAIF Partners’ proposals to remove the Company’s incumbent directors and to elect SAIF Partners’ slate of ten highly qualified director nominees to the Board of Directors (the “Board”) at Sinovac’s Special Meeting of Shareholders (the “Special Meeting”).

On July 8, 2025, at 8:00 p.m. Atlantic Standard Time, Sinovac’s incumbent Chairman Chiang Li convened, then immediately purported to adjourn, the Special Meeting without allowing shareholders to participate. SAIF Partners representatives, alongside those of other shareholders, had arrived at the Special Meeting intending to participate in the meeting.

Subsequently, the shareholder representatives present convened a continuation of the Special Meeting, chaired by incumbent Sinovac Director Mr. Yuk Lam Lo, the only remaining director on the incumbent Board approved by Privy Council. During the Special Meeting, Sinovac’s shareholders voted to approve both of SAIF Partners’ proposals, based on a tabulation of votes cast on SAIF Partners’ gold proxy card and the Company’s white proxy card.

The newly elected directors of the Company are committed to supporting and executing Sinovac’s announced payout of dividends and working closely with Sinovac’s management to unlock long-term value for all shareholders by pursuing the resumption of trading of the Company’s common shares to help Sinovac realize its tremendous potential.

About SAIF Partners

SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices.

Contacts

Media Contacts
Jonathan Gasthalter/Mark Semer/Grace Cartwright
Gasthalter & Co.
+1 (212) 257 4170
SAIF@gasthalter.com

Investor Contacts
Paul Schulman/Bill Dooley/Jon Eyl
Sodali & Co.
+ 1 (203) 658-9400
SAIF@info.sodali.com

SAIF Partners IV L.P.

NASDAQ:SVA

Release Versions

Contacts

Media Contacts
Jonathan Gasthalter/Mark Semer/Grace Cartwright
Gasthalter & Co.
+1 (212) 257 4170
SAIF@gasthalter.com

Investor Contacts
Paul Schulman/Bill Dooley/Jon Eyl
Sodali & Co.
+ 1 (203) 658-9400
SAIF@info.sodali.com

More News From SAIF Partners IV L.P.

CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac

NEW YORK--(BUSINESS WIRE)--Third paragraph, second sentence of release should read: These include the current Board’s failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac’s prior public accounting firm to resign in April, and its poor governance practices. The updated release reads: SAIF PARTNERS: NOW IS YOUR LAST CHANCE TO VOTE FOR BOARD CHANGE AT...

SAIF Partners Sends Letter to Sinovac Shareholders

NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board’s empty promises to shareholders, numerous failures overseeing the Company, and certain directors’ concerning patterns of reckless, unethical and illegal actions to retain control of Sinovac. The full tex...

SAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board’s Failure to Act in the Interests of Shareholders

BEIJING--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to its fellow Sinovac shareholders exposing the current Sinovac Board’s failure to act in the interest of all shareholders resulting in failure to pay shareholders dividends and to resume trading of the shares after a six-year halt. This is a stark contrast...
Back to Newsroom